US Patent 4,070,462: Claim Scope, Expiration, Orange Book Relevance, and Betamethasone Formulation Landscape

US Patent 4,070,462 covers topical anti-inflammatory methods and ointments containing a betamethasone ester in a substantially anhydrous petrolatum-based vehicle. Its core formulation requires a glycol solvent, propylene glycol monostearate, optional wax, and petrolatum. The patent issued on January 24, 1978, and its standard 17-year term expired on January 24, 1995. It therefore presents no current US patent-enforcement barrier to generic or follow-on products.

What does US Patent 4,070,462 protect?

The patent has three claim groups:

Claim group	Claims	Subject matter
Method of treating inflammation	1-6	Applying the specified ointment to inflamed skin
Topical ointment composition	7-12	The ointment itself
Treatment of psoriasis	13-18	Applying the ointment to treat psoriasis

The technical center of the patent is a non-aqueous, water-miscible solvent-in-oil base containing:

A glycol solvent;
Propylene glycol monostearate;
Petrolatum;
Optional white or yellow wax; and
A dermatologically acceptable 17-monoester or 17,21-diester of betamethasone.

The principal disclosed active ingredients are betamethasone 17,21-dipropionate and betamethasone 17-valerate, commonly referred to as betamethasone valerate.

What are the required formulation limitations?

Claim 1 formulation

Claim 1 requires a method using a topical formulation with:

Component	Claimed amount or identity
Betamethasone ester	Amount effective to treat inflammation
Glycol solvent	15%
Glycol options	1,2-propylenediol, butylene glycol, hexylene glycol, or mixtures
Propylene glycol monostearate	1%-3%
White or yellow wax	0%-7%
Petrolatum	70%-90%
Dosage form	Non-aqueous, water-miscible solvent-in-oil base

Claim 1 is narrower than claim 7 because it recites 15% glycol solvent rather than the 5%-15% range appearing in claim 7.

Claim 7 formulation

Claim 7 covers the ointment composition itself. Its principal ranges are:

Component	Claim 7 limitation
Glycol solvent	5%-15%
Propylene glycol monostearate	1%-3%
White or yellow wax	0%-7%
Petrolatum	70%-90%
Betamethasone ester	Therapeutically effective amount

Claim 7 is the broadest independent composition claim. A product would need to satisfy every required limitation to fall within its literal scope.

How do the dependent claims narrow the patent?

Claim	Limitation
2	Betamethasone 17,21-dipropionate
3	Betamethasone valerate
4	Active ingredient at 0.01%-0.2% by weight
5	1,2-propylenediol as the glycol
6	White wax
8	Betamethasone 17,21-dipropionate
9	Betamethasone 17-valerate
10	Active ingredient at 0.01%-0.02% by weight
11	1,2-propylenediol
12	White wax
13-18	Psoriasis treatment using the composition or specified dependent composition

Claims 13-18 do not materially broaden the formulation protection. They add psoriasis as the treatment indication. Because they depend on claim 7 or one of its dependent claims, they inherit all base-composition limitations.

What is the scope of “comprising” in the claims?

The claims use “comprising” for the overall formulation. That normally permits additional ingredients, provided the accused formulation still contains every recited component and does not otherwise avoid the claim.

The phrase “consisting essentially of” applies to the glycol-solvent definition. That language is narrower than “comprising” and can exclude additional solvents that materially alter the basic properties of the claimed solvent system. A formulation with propylene glycol plus a minor incidental solvent may present a different question from a formulation deliberately using a second non-glycol solvent as a primary vehicle.

The claims do not require a particular manufacturing process, particle size, release profile, packaging system, pH, preservative, or penetration enhancer. Their protection is composition- and use-focused.

Which betamethasone products fall within the claimed chemical classes?

Betamethasone 17,21-dipropionate

Betamethasone dipropionate is expressly identified in claims 2 and 8. It is the active ingredient associated with augmented topical corticosteroid products, including ointments, creams, lotions, gels, and sprays.

A formulation containing betamethasone dipropionate does not automatically infringe. It must also contain the claimed vehicle system, including the glycol solvent, propylene glycol monostearate, petrolatum, and any other limitations of the relevant claim.

Betamethasone valerate

Claims 3 and 9 cover betamethasone valerate, described in claim 9 as betamethasone 17-valerate. Betamethasone valerate products may use different vehicles, emulsions, creams, lotions, or gels. Those products would fall outside the claims if they lack the required non-aqueous petrolatum-based system or the specified excipient combination.

Other betamethasone esters

The independent claims use the broader category of a “17-mono or 17,21-diester of betamethasone.” That wording may reach additional esters beyond the expressly named dipropionate and valerate, subject to claim construction and the requirement that the compound be dermatologically acceptable and used in the claimed formulation.

The dependent claims do not limit the independent claims to only the two expressly named esters.

When did US Patent 4,070,462 lose exclusivity?

US Patent 4,070,462 issued January 24, 1978. For a US utility patent governed by the pre-Uruguay Round patent-term rule, the term was generally 17 years from grant. On that basis, the patent expired January 24, 1995.

Event	Date
Patent grant	January 24, 1978
Standard term	17 years from grant
Estimated expiration	January 24, 1995
Current enforceability	Expired

The patent predates the Hatch-Waxman patent-term framework and the modern 20-year-from-earliest-effective-filing-date rule. Patent term extension under 35 U.S.C. § 156 does not revive an expired patent, and the patent’s age makes current term restoration commercially irrelevant.

What is the Orange Book status of US Patent 4,070,462?

US Patent 4,070,462 should not be treated as a current Orange Book patent barrier. Orange Book listings are tied to approved drug products and their applicable patents, including patents claiming the drug substance, drug product, or approved method of use under FDA listing rules.

An expired 1978 formulation patent cannot block an ANDA solely because it once covered a topical betamethasone product. A generic applicant would address any currently listed patents for the relevant reference-listed drug, not rely on the expired term of US 4,070,462.

The patent may remain historically relevant to the formulation lineage of topical betamethasone ointments, but historical relevance is distinct from current Orange Book enforceability. FDA approval status, therapeutic equivalence, and current listed patents must be evaluated at the level of the specific reference product and NDA.

Are Paragraph IV challenges relevant to this patent?

No. A Paragraph IV certification is relevant to a patent that remains listed and unexpired for the reference drug. Because US Patent 4,070,462 expired in 1995, it cannot support a current Paragraph IV exclusivity dispute.

A generic applicant could have confronted this patent during its effective term, but any present ANDA challenge would focus on later patents, if any, listed for the relevant topical betamethasone product. Those later patents could concern:

A particular ointment vehicle;
An augmented formulation;
A spray or lotion delivery system;
A method of treating a defined dermatologic condition;
Manufacturing or particle-size controls; or
A specific combination of active ingredient and excipients.

What formulation is protected by the patent?

The strongest formulation position is the combination in claim 7:

Betamethasone ester;
5%-15% glycol solvent;
1%-3% propylene glycol monostearate;
0%-7% white or yellow wax; and
70%-90% petrolatum.

The claims describe a solvent-in-oil ointment rather than a conventional oil-in-water cream. The glycol provides a water-miscible solvent phase within the predominantly petrolatum vehicle. Propylene glycol monostearate functions as an emulsifying or structuring component. Wax can modify consistency and occlusivity.

A formulation with petrolatum and propylene glycol but without propylene glycol monostearate would have a strong noninfringement position against the composition claims, assuming no doctrine-of-equivalents issue. A cream containing a substantial aqueous phase would also present a strong distinction from the expressly non-aqueous base.

What technical vulnerabilities exist in the claims?

Internal range inconsistency

Claim 1 recites 15% glycol solvent, while claim 7 recites 5%-15%. This is not necessarily fatal because the claims are separate and claim 1 may be read as requiring the upper endpoint. It does create a drafting distinction between the method claim and composition claim.

Claim 4 recites 0.01%-0.2% active, while claim 10 recites 0.01%-0.02%. Claim 10 is narrower and falls within claim 4 if the claims are otherwise properly dependent.

Active concentration mismatch

The claimed active ranges may not align with every marketed betamethasone formulation. A product containing 0.05% betamethasone dipropionate could fall within claim 4 but outside claim 10.

Exact excipient requirement

The requirement for propylene glycol monostearate is significant. Many topical corticosteroid products use different emulsifiers, gelling agents, mineral oils, or surfactants. A product with the same active ingredient and petrolatum base may avoid the claims if it lacks this specified excipient.

“Consisting essentially of” limitation

The glycol-solvent language may create a construction issue where a formulation contains multiple solvents. The analysis would depend on whether the additional solvent materially changes the basic characteristics of the claimed vehicle.

Claim 13 psoriasis limitation

Claims 13-18 require treatment of psoriasis. They would not be infringed by use for eczema or another inflammatory condition unless the relevant claim’s method language and factual use support the psoriasis limitation. The composition claims in claims 7-12 do not contain that disease-specific limitation.

How strong is the patent estate today?

The current estate strength is effectively zero as an enforcement asset because the patent expired nearly three decades ago.

Factor	Assessment
Core formulation coverage	Specific and technically identifiable
Active ingredient coverage	Broad at the independent-claim level, with named ester species in dependent claims
Excipient coverage	Narrow because of propylene glycol monostearate requirement
Method-of-use coverage	Inflammation broadly; psoriasis specifically in claims 13-18
Manufacturing protection	None apparent from the supplied claims
Geographic coverage	United States only
Current patent term	Expired
Current generic blocking value	None
Historical formulation value	Moderate
Current licensing value	Minimal absent separate unexpired rights

The patent also has no international effect. Foreign counterparts, if any, would have required separate prosecution and would have expired under their respective national terms.

What litigation, settlements, and licensing issues affect the patent?

No current litigation or settlement rights can arise from the expired patent itself. An expired patent cannot support an injunction, damages claim for post-expiration conduct, or a current Paragraph IV settlement obligation.

Any historical license involving the patent would need to be analyzed separately. Patent expiration removes the patent exclusion right but does not automatically eliminate independent contractual obligations, such as royalty provisions, confidentiality terms, supply commitments, or releases. The supplied claim record contains no licensing or settlement information.

What generic launch risks exist for betamethasone ointments?

A generic manufacturer faces little risk from US Patent 4,070,462. The meaningful risks would arise from other rights associated with a specific reference product:

Risk category	Relevance
Expired formulation patent	No current barrier
Later formulation patent	Potentially relevant
Method-of-use patent	Relevant only if listed, unexpired, and applicable
Orange Book patent listing	Must be reviewed for the target NDA
FDA sameness requirements	Potentially significant for topical products
Bioequivalence or comparative clinical endpoint	Product-specific
Manufacturing process patent	Relevant if unexpired and practiced
Trademark or trade dress	Separate from patent rights
Regulatory exclusivity	Product- and approval-specific

Topical generic products may face formulation and bioequivalence challenges even when patent risk is low. The FDA may evaluate sameness or equivalence of active ingredient, dosage form, strength, route, inactive ingredients, and performance characteristics under the applicable abbreviated pathway.

How does this patent compare with modern topical corticosteroid patent strategies?

US Patent 4,070,462 uses classic formulation claiming. It protects a defined active-excipient combination and related therapeutic applications.

Modern topical drug patent portfolios more often divide protection among:

Active pharmaceutical ingredient forms;
Particle engineering;
Vehicle systems;
Delivery devices;
Spray or foam platforms;
Release-rate characteristics;
Skin penetration or deposition;
Combination therapy;
Manufacturing controls; and
Narrow patient or disease subgroups.

The 1978 patent has no apparent device, process, particle, packaging, or pharmacokinetic claims. Its commercial value depended on the specific ointment vehicle rather than on a broad exclusivity platform.

Key Takeaways

US Patent 4,070,462 covers betamethasone ester ointments using a glycol solvent, propylene glycol monostearate, petrolatum, and optional wax.
Claims 1-6 cover methods of treating inflammation.
Claims 7-12 cover the ointment composition.
Claims 13-18 cover psoriasis treatment using the claimed ointment.
Betamethasone 17,21-dipropionate and betamethasone valerate are expressly covered by dependent claims.
The patent issued January 24, 1978, and expired approximately January 24, 1995.
It presents no current US patent or Paragraph IV barrier.
The excipient combination, especially propylene glycol monostearate, is the principal limiting feature.
Later patents associated with a particular NDA, formulation, delivery system, or method of use must be analyzed separately.
The patent has historical formulation significance but no meaningful current exclusionary value.

FAQs

Does US Patent 4,070,462 cover all betamethasone dipropionate ointments?

No. The ointment must also contain the claimed glycol solvent, propylene glycol monostearate, petrolatum, and other required formulation characteristics.

Is a 0.05% betamethasone dipropionate ointment within the claimed concentration range?

It may fall within claim 4, which recites 0.01%-0.2%, but it does not fall within claim 10, which recites 0.01%-0.02%. The remaining formulation limitations must also be satisfied.

Does the patent cover betamethasone valerate cream?

Not automatically. A cream may avoid the claims if it has an aqueous phase or lacks propylene glycol monostearate, the required glycol range, or the petrolatum-dominant vehicle.

Can an expired patent remain listed in the Orange Book?

An expired patent may appear historically in regulatory records, but it cannot provide a current exclusion right. The commercial effect depends on the current listing status and the applicable NDA.

Does the patent protect manufacturing methods for the ointment?

The supplied claims do not recite a manufacturing process. They protect the composition and methods of applying it to treat inflammation or psoriasis.

References

United States Patent and Trademark Office. (1978). Topical anti-inflammatory compositions, U.S. Patent No. 4,070,462.
United States Congress. (2023). 35 U.S.C. § 154: Contents and term of patents; provisional rights.
United States Congress. (2023). 35 U.S.C. § 271(e): Infringement of patent relating to drugs and veterinary biological products.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations, patent and exclusivity information. FDA.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2999177	⤷ Start Trial
Australia	509635	⤷ Start Trial
Belgium	860071	⤷ Start Trial
Switzerland	627652	⤷ Start Trial
Germany	2747631	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,070,462

Summary for Patent: 4,070,462